Inventiva SA, of Daix, France, said it completed a capital increase of €625,000 (US$683,350) subscribed by Sofinnova Partners, through Sofinnova Crossover I SLP. The funds will be primarily used for general corporate purposes, including funding operations and the development of the company's products, especially lanifibranor and odiparcil in nonalcoholic steatohepatitis and mucopolysaccharidosis, respectively.